Summary
- Profile Type
- Business Offer
- POD Reference
- BOTW20260721001
- Term of Validity
- 21 July 2026 - 21 July 2027
- Company's Country
- Taiwan
- Type of partnership
- Commercial agreement
- Supplier agreement
- Targeted Countries
- All countries
General information
- Short Summary
- A biotechnology manufacturer specializes in high-fidelity raw materials for advanced therapeutics and diagnostics. Core products include GMP-grade recombinant proteins for cell therapy, mRNA synthesis components (saRNA, CRISPR/Cas), exosome tools, and IVD reagents.
- Full Description
-
Background & Core Competence: A Taiwanese biotechnology manufacturer specializes in the research, development, and commercial-scale production of high-fidelity biological raw materials. The company supports advanced therapeutic development, life science research, and in vitro diagnostics (IVD).
Key Technology Pillars & Product Offerings:
1. mRNA & Gene Editing Platforms: The company provides a comprehensive suite of tools for next-generation genetic medicine. This includes self-amplifying mRNA (saRNA), reporter gene mRNA, and specialized gene-editing mRNA components targeting CRISPR-Cas systems (specifically Cas12a and dCas9-KRAB platforms). The portfolio is supported by essential synthesis enzymes such as T7 RNA polymerase, RNA ladders, and proprietary lipid-based transfection reagents optimized for high-efficiency cellular uptake.
2. Recombinant Proteins for Cell Therapy: A core manufacturing competency is the expression and purification of GMP-grade and Research Use Only (RUO) recombinant proteins. The pipeline focuses heavily on critical raw materials for cell and gene therapies (CGT), including interleukins, cytokines, chemokines, and growth factors. These proteins are engineered for high bioactivity, batch-to-batch consistency, and ultra-low endotoxin levels required for clinical manufacturing protocols.
3. Exosome & VHH Technologies: The enterprise has developed specialized isolation and purification technologies, notably exosome purification kits and VHH (Nanobody) Sepharose beads. These tools enable researchers to efficiently capture and analyze extracellular vesicles, supporting downstream diagnostic and therapeutic applications with higher stability than traditional antibody formats.
4. Molecular Diagnostic & Immunological Reagents: To support the IVD sector, the firm supplies bulk raw materials for PCR, qPCR, and RT-LAMP platforms, including optimized nucleotides and sample preparation buffers. The immunological portfolio encompasses highly specific primary and secondary antibodies, internal control antibodies (such as Taq antibodies), and disease-specific antigens utilized in ELISA and lateral flow rapid test formats. - Advantages and Innovations
-
Vertical Integration: End-to-end in-house control from construct design to final lyophilization ensures supply chain security and competitive pricing without relying on third-party API sourcing.
Advanced CRISPR/mRNA Capabilities: Differentiated expertise in synthesizing complex mRNA constructs, including custom saRNA and specialized Cas-nuclease mRNAs, accelerating partner R&D timelines.
Stringent GMP Compliance: Recombinant protein production aligns with strict regulatory standards, delivering ultra-low endotoxin (<0.1 EU/µg) and carrier-free formulations critical for advanced cell therapy manufacturing.
Proprietary Affinity Platforms: The utilization of VHH (Nanobody) technology provides superior binding affinity and stability compared to traditional antibody formats, particularly in complex sample matrices for exosome research. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 17: Partnerships to achieve the Goal
Partner Sought
- Expected Role of a Partner
- Biopharmaceutical Companies & Advanced Therapy Developers: Seeking partners requiring GMP-grade recombinant proteins or customized mRNA constructs for integration into cell therapy manufacturing workflows under a manufacturing or commercial agency agreement. In Vitro Diagnostic (IVD) Manufacturers: Looking for diagnostic companies to integrate the firm's PCR, RT-LAMP, and antigen/antibody raw materials into their commercial test kits via out-licensing or supplier agreements. Research Institutes & Universities: Seeking academic or institutional partners focusing on exosome research, CRISPR-based gene editing, or transcriptomics for joint research and development (R&D) agreements.
- Type and Size of Partner
- Big company
- SME 50 - 249
- SME <=10
- University
- SME 11-49
- R&D Institution
- Type of partnership
- Commercial agreement
- Supplier agreement
Dissemination
- Technology keywords
- 06001024 - Medical Biomaterials
- 06004 - Micro- and Nanotechnology related to Biological sciences
- Market keywords
- 04007 - Enzymology/Protein Engineering/Fermentation
- 04017 - Micro- and Nanotechnology related to Biological sciences
- 04004 - Other Genetic Engineering
- 04006 - Cellular and Molecular Biology
- Targeted countries
- All countries
